Wedbush Maintains Outperform on Aprea Therapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Aprea Therapeutics (NASDAQ:APRE) and raises the price target from $9 to $11.
March 27, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Aprea Therapeutics and raises the price target from $9 to $11.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100